Tate & Lyle buys healthy food competitor – how did markets react?
Food ingredients group Tate & Lyle has scooped up a competitor to benefit from growing demand for healthier food


Tate & Lyle’s shares fell by 9% after it confirmed that it will focus on healthy food products by buying ingredients supplier CP Kelco for $1.8 billion, say Helen Cahill and Isabella Fish in The Times. Tate & Lyle says the deal will help it meet a target of annual revenue growth of between 4% and 6% by capitalising on mounting demand for healthier foods.
It also hopes that buying CP Kelco will expand the group’s range of products that can help “sweeten foods, provide the right texture and improve fibre content”. The deal comes amid intensifying scrutiny of ultra-processed foods such as flavoured yoghurts and sweet snacks, with research increasingly linking them to diseases including cancer and Type 2 diabetes, says Eri Sugiura in the Financial Times.
Tate & Lyle says the problem lies with “the lack of nutritional content rather than the processing itself”, and that CP Kelco’s technologies “would help them develop new products addressing this”. The deal will also help grow Tate & Lyle’s footprint in fast-growing emerging markets.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
How are Tate & Lyle shareholders reacting?
Tate & Lyle hopes the deal will ensure the combined entity can supply “producers looking to make food that is healthier but still tasty enough to fly off the shelves”, says AJ Bell’s Russ Mould. But the scale of the deal is “clearly making some investors nervous” – large deals “have a nasty habit of destroying rather than creating shareholder value”.
The fact that the deal is being funded through a mixture of debt and cash means it will lead to extra strain on Tate & Lyle’s balance sheet. Much depends on its ability to deliver savings by combining operations, as well as the promised improvements in revenue growth and margins. The deal’s returns “look underwhelming”, says Aimee Donnellan on Breakingviews.
After all, CP Kelco has struggled recently, with its operating profit falling to $62 million in 2023. Even if you add $50 million of expected cost synergies, the $1.8 billion outlay only yields a 5% return, which is “a long way” from Tate & Lyle’s 9% cost of capital. Still, you could argue that CP Kelco is only in a “temporary slump”, and with inflation falling, next year’s return could be near 8%, suggesting the takeover “has at least a path to passing the taste test”.
The deal, combined with the sale of its Primient joint venture, completes Tate & Lyle’s “transformation into a fully-fledged speciality food and beverage solutions business”, says Hargreaves Lansdown’s Matt Britzman. This will enable it to benefit from its close relationships with customers, which “add an element of stickiness to the business”, while leveraging its technical expertise.
A “strong” management team, and a balance sheet “with enough firepower to expand” also give “scope for optimism”. Still, it will take some “knockout performances” for sentiment to shift.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
Families suffer £20,000 lost income growth – are you feeling the pinch?
Average incomes for working age families have increased by just 7% in the past two decades, research suggests
-
How to achieve a secure retirement, as more retirees admit to struggling with debt
Twenty-six percent of retirees now have unsecured debt – a sharp rise compared to two years ago – with many underestimating how much a typical retirement costs
-
Small UK industrial stocks are hidden gems
Opinion Ed Wielechowski of the Odyssean Investment Trust highlights three of his favourite British small-cap industrial stocks
-
Aurora Innovation is running on empty – is it overvalued?
Aurora Innovation, a maker of self-driving trucks, may have promised far more than it can deliver
-
'Ride the recovery in emerging markets': Gustavo Medeiros of Ashmore Group tells MoneyWeek
Interview What's the outlook for emerging markets? Gustavo Medeiros, head of research at Ashmore Group, gives his analysis and reviews progress in developing economies
-
What is the Enterprise Investment Scheme and should you have one?
The Enterprise Investment Scheme is tax-efficient and potentially lucrative. Taking a chance on the scheme could trim your family’s IHT bill, says David Prosser
-
The alcohol industry is suffering as consumers sober up – is it still worth investing in the sector?
Changing consumer tastes are rocking the alcohol industry, but the best players are adapting their strategies. Buy them while their shares are still cheap
-
A strange calm in credit
Corporate bond markets remain remarkably relaxed, with yields that offer little compensation for risks
-
'The City's big bet on green finance fails to pay out'
Opinion Insurers and banks are backing away from “green finance”, and there is not much sign of the green boom we were promised. That’s a problem for the City
-
Six top investment trusts for smaller stocks
Liquidity constraints mean investment trusts are best placed to seize the juiciest opportunities